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Abstract
Aims—Smoking prevalence is higher among persons enrolled in addiction treatment as compared 
to the general population, and very high rates of smoking are associated with opiate drug use and 
receipt of opiate replacement therapy (ORT). We assessed whether these findings are observed 
internationally.
Methods—PubMed, PsycINFO and the Alcohol and Alcohol Problems Science Database were 
searched for papers reporting smoking prevalence among addiction treatment samples, published 
in English, from 1987 to 2013. Search terms included tobacco use, cessation, and substance use 
disorders using AND/OR Boolean connectors. For 4,549 papers identified, abstracts were 
reviewed by multiple raters. 239 abstracts met inclusion criteria and these full papers were 
reviewed for exclusion. 54 studies, collectively including 37,364 participants, were included. For 
each paper we extracted country, author, year, sample size and gender, treatment modality, primary 
drug treated, and smoking prevalence.
Results—The random-effect pooled estimate of smoking across persons in addiction treatment 
was 84% (CI 79%, 88%), while the pooled estimate of smoking prevalence across matched 
population samples was 31% (CI 29%, 33%). The difference in the pooled estimates was 52% (CI 
48%, 57%, p < .0001). Smoking rates were higher in programs treating opiate use as compared to 
alcohol use (OR = 2.52, CI 2.00, 3.17), and higher in ORT compared to outpatient programs (OR 
= 1.42, CI 1.19, 1.68).
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Conclusions—Smoking rates among people in addiction treatment are more than double those 
of people with similar demographic characteristics. Smoking rates are also higher in people being 
treated for opiate dependence compared with people being treated for alcohol use disorder.
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INTRODUCTION
Each year, nearly 6 million people worldwide die from tobacco-related causes. Tobacco use 
accounts for about 18%, 11%, and 4% of deaths in high-, middle-, and low-income 
countries, respectively (1). Economic damages from global tobacco use are estimated at over 
one half trillion dollars per year (2). To address the global health and economic costs of 
tobacco the World Health Organization (WHO) approved the Framework Convention on 
Tobacco Control (FCTC), an international treaty that monitors global tobacco consumption 
and tobacco control policies and crafts measures to reduce tobacco supply and demand. The 
FCTC's six principal strategies, called “MPOWER,” include smoke-free environments, 
cessation programs, warning labels, mass anti-tobacco media, tobacco advertising bans, and 
taxation (2).
In concert with the FCTC, the Global Adult Tobacco Survey (GATS) has become an 
important tool for cross-national studies of smoking prevalence and tobacco policies. A 
recent analysis of GATS data demonstrated high variability in smoking rates across 14 low- 
and middle-income countries, with smoking prevalence ranging from 21.6% to 60.2% 
among men and from <1% to 24.4% among women (3). Similar to the GATS, European 
researchers developed the Tobacco Control Scale (TCS) to evaluate smoking prevalence 
across European Union nations (4-7). While both the GATS and TCS evaluate smoking 
prevalence cross-nationally, there are no systematic approaches to compare international 
smoking rates in subgroups where smoking is most prevalent. These subgroups include, but 
are not limited to, persons with mental health and substance abuse disorders (8, 9).
Concerning substance abuse specifically, studies in the United States (U.S.) indicate that 
smoking rates are 2 to 4 times higher in persons with substance use disorders than in the 
general public (9, 10). Smoking rates are highest, however, among those with substance use 
disorders who also enter addiction treatment, with smoking prevalence in this subgroup 
estimated at around 67% (11). Smokers with comorbid substance abuse are more likely to 
die from tobacco-related causes than from other substance-related causes (12, 13), and 
quitting smoking is associated with longer-term maintenance of recovery from other 
addictions (14).
We previously conducted a systematic review of smoking in addiction treatment in the U.S. 
from 1987 through 2009 (15). Focusing on 42 papers, and aggregating samples by year, we 
found annual smoking rates ranging from 65 to 87.2% with a median of 76.3%. This was 
consistent with National Survey on Drug Use and Health (NSDUH) data, where smoking 
prevalence among persons who received recent addiction treatment ranged from 68.9% in 
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2000 to 74.2% in 2011 (15, 16). The current study estimates smoking prevalence for persons 
entering addiction treatment internationally, using studies published between 1987 and 2013, 
and compares prevalence reported in treatment samples to national epidemiologic estimates. 
Such a review may be useful for directing tobacco control resources and policies to 
concentrations of smokers who seek treatment for other addictions.
METHODS
Article Identification and Selection
Search Procedures—PubMed, PsycINFO and the ETOH Alcohol and Alcohol Problems 
Science Database (an archived database of alcohol-related research) were searched for 
published papers reporting smoking prevalence for addiction treatment samples. These 
sources contain the title and abstract for each paper in the database, so the electronic search 
was limited to titles and abstracts in each database. Specific search terms were used for each 
database, reflecting their respective search term mapping, and we identified the broadest 
search terms relevant to our goals. PubMed MeSH terms and Boolean connectors included 
“smoking OR tobacco use cessation OR tobacco use disorder OR tobacco OR nicotine” 
AND “substance-related disorders OR substance abuse treatment centers” AND “patients.” 
PsycINFO Thesaurus descriptors used included: “addiction OR drug usage” AND “client 
attitudes OR clients OR patients” AND “nicotine OR tobacco smoking OR smoking 
cessation.” The Alcohol and Other Drug Thesaurus (AOD) descriptors were used for the 
ETOH search and consisted of: “(tobacco in any form or smoking or nicotine)” AND 
“(survey or questionnaire or interview or self-report).” Search results were limited to articles 
published in English. Papers from all countries were included in the screening process. A 
total of 4,541 papers were identified electronically, and 20 additional papers were identified 
through bibliographic review of the final selected papers. After removing duplicates, 
abstracts for 4,549 articles were screened for inclusion. Systematic review procedures were 
conducted in accordance with PRISMA guidelines, and Figure 1 shows the PRISMA flow 
diagram (17).
Rating Abstracts for Inclusion—Abstracts were reviewed using three inclusion criteria: 
(a) the paper reported data gathered in an addiction treatment setting, (b) patient-level data 
were reported, and (c) tobacco use was mentioned in the abstract. Only abstracts meeting all 
three criteria were reviewed further. Abstract review procedures were conducted for two 
time periods, first for the years 1987-2009, and again for the period 2009 through June of 
2013.
To assess inter-rater reliability for the first period (1987-2009), 6 raters were trained on 
inclusion criteria and then rated the same set of 30 abstracts (ICC = 0.83, p < .001). 
Thereafter, each rater rated a unique set of 300 abstracts, with a final test of inter-rater 
reliability to assess potential rater drift during the rating process (ICC = 0.79, p< .001) (15). 
To assess inter-rater reliability for the second period (2009 - 2013), 4 raters (3 were the same 
and 1 different) were trained on inclusion criteria and then rated the same set of 20 abstracts 
(ICC = 1.0). Thereafter, each rater rated unique sets of abstracts. Last, inter-rater reliability 
was assessed using a single set of 20 abstracts, to assess potential rater drift (ICC = 1.0).
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Reviewing Papers for Exclusion—A total of 239 met abstract inclusion criteria. Each 
of these papers was read by one of two reviewers, with attention to four exclusion criteria: 
(a) a review paper (not primary data); (b) smoking prevalence not reported for addiction 
treatment sample; (c) participant selection was based on smoking status; (d) participants 
were adolescents. Of the 61 papers remaining eligible, one was excluded due to a small 
sample size (defined for this review as less than 25 participants) (18), and one multinational 
paper was excluded because it did not report smoking prevalence of the sample by country 
where data were collected (19). Five papers were excluded due to overlapping sample with 
another paper included in the review (20-24). A total of 54 papers from 20 countries are 
included in the review. Search terms and the checklists used for rating abstracts and 
reviewing papers are available from the first author.
National Smoking Prevalence Data
Each study in the review provides smoking prevalence for a sample of persons enrolled in 
addiction treatment, in one country and in one year. We compared smoking prevalence in 
each study sample to national smoking prevalence for the same country and in the same 
year. Smoking prevalence differs widely by gender in many countries. When the addiction 
treatment sample included ≥ 70% women we used national prevalence estimates for women 
(5 studies), and when the sample included ≥ 70% men we used the national prevalence 
estimate for men (35 studies). When the sample included 31-69% of either women or men 
(10 studies) (25-34), or when the gender breakdown was unknown (4 studies) (35-38), we 
used a national prevalence estimate for men and women combined.
To obtain national smoking prevalence rates we first consulted the World Health 
Organization (WHO) Global Health Observatory Data Repository (http://apps.who.int/gho/
data/view.main). Within the Repository we referred to the Tobacco Control section, and to 
the Prevalence – adult age-standardized by country dataset which reports current smoking 
for male, female and both sexes. However, these data refer only to 2006, 2009 and 2011. For 
national smoking prevalence from additional years we consulted the 2011 Country Profiles 
from the WHO Report on Global Tobacco Epidemic (http://www.who.int/tobacco/
global_report/2011/en/). Where national prevalence rates were not available through these 
WHO sources, we consulted the web edition of the International Smoking Statistics (ISS) 
(http://www.pnlee.co.uk/ISS.htm). If rates were not available the WHO or ISS sources, we 
consulted official country websites. Finally, rates reported in published articles were used if 
rates could not be found through other sources. Smoking prevalence estimates were not 
available for all countries in all years. For 30 papers we found national smoking prevalence 
in the year the study was published. For 21 papers we found prevalence estimates within one 
year, and for 3 papers we found prevalence estimates within two years of the publication 
year.
To calculate Confidence Intervals (CIs) for national smoking prevalence, we found the report 
where each estimate originated. We used either the total N from the original survey, or the N 
for men or women, according to the gender matched prevalence for each study. For 13 
papers where the original source was not found, was found behind a paywall, or was found 
in a language we could not translate using Google Translate, we used N = 4000 to calculate 
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CIs. This is the lower bound of the Ns that were found and so represents a conservative 
approach to estimating the population Cis. When the sample size for the national survey was 
not reported by gender, we estimated the N for each gender by halving the total.
Data Analysis
Country, year of publication, author, sample size, proportion of women, and smoking 
prevalence were extracted for each paper. For papers reporting intervention studies, or for 
papers reporting repeated measures over time, we used prevalence from the baseline data. 
Treatment modality (inpatient, outpatient, opiate replacement therapy), and primary drug 
treated (alcohol, alcohol and other drugs, opiates) were also extracted. Opiate replacement 
therapy (ORT) is an outpatient modality distinguished by its focus on replacing illicit opiates 
with either methadone or buprenorphine. Where papers drew clients from two modalities, 
they were coded to whichever category represented more than half of the patients involved in 
the article (39, 40). Two papers reporting cocaine as the primary drug treated were grouped 
in the “alcohol and other drug” category (41, 42).
We extracted the smoking prevalence and calculated the 95% CI for each estimate. Using a 
Forest plot, we plotted the smoking prevalence and CI for each paper alongside the year and 
gender-matched national smoking prevalence for the country where the paper was reported. 
Using these estimates and CIs, we calculated the random-effect pooled estimates for 
smoking across addiction treatment samples, across national prevalence estimates, and the 
difference between the two (study – national).
Research in the U.S. has shown that opiate use as compared to alcohol use, and enrollment 
in opiate replacement therapy (ORT) as compared to non-opiate outpatient programs, were 
associated with higher smoking prevalence (16, 43). To assess whether these associations 
may also be observed internationally, we calculated smoking rates by treatment modality 
and primary drug treated combined across all papers. Treatment modality and primary drug 
treated were intercorrelated (r = .55, p < .0001), so each variable was evaluated in a separate 
model before both were included in the same model. Random-effect logistic regression 
models were used to assess univariate relationships between each predictor (treatment 
modality, primary drug, year of study) and smoking prevalence, and then to assess 
multivariate relationships of treatment modality and primary drug with smoking prevalence, 
controlling for year. In these analyses a random intercept model was used, with country as a 
random factor. Two papers were removed from analyses because they reported on patient 
samples that were aggregated over 20 years, confounding any relationship between time in 
those samples (39, 44). One paper from 1989 was removed (45) so that the analysis period 
would be 20 years in length (1994 – 2013) and most years would be represented by at least 
one study. We conducted these analyses with nesting by country.
RESULTS
Prevalence of Smoking in Addiction Treatment
Papers in the review are summarized in Table 1, listed alphabetically by country and, within 
country, by year published. Among the studies were 6 from Germany, 5 each from Australia 
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and Italy, and 4 each from Brazil, France, Switzerland and the UK. The remaining 22 papers 
were from 13 different countries. Programs were identified in the reports as inpatient (41%), 
methadone or other opiate treatment (30%) or outpatient programs (26%). Type of program 
could not be determined for 2 studies (46, 47). Programs identified the primary drug treated 
as alcohol (48%), heroin or other opiates (35%), or alcohol and other (non-specified) drugs 
(17%). The final column shows the year and age matched national smoking prevalence for 
the country in which each study was reported. Smoking prevalence across all studies ranged 
from 41.1% (39) to 100% (46, 48).
Figure 2 compares smoking prevalence visually in each sample to the corresponding 
national prevalence. National prevalence rates are shown on the left, while study prevalence 
rates and 95% CIs are on the right. For each study, the white space between the two 
estimates represents how much higher smoking is in the addiction treatment sample as 
compared to the general population. Scanning this white space from top to bottom shows 
that smoking rates are consistently higher in addiction treatment. Not shown in the Figure, 
the random-effect pooled estimate of smoking across persons in addiction treatment was 
84% (CI 79%, 88%). The pooled estimate of smoking prevalence across the year and 
gender-matched population samples was 31% (CI 29%, 33%), and the difference in pooled 
estimates was 52% (CI 48%, 57%, p < .0001).
Association of Smoking with Treatment Modality and Primary Drug
Smoking rates were 85% in ORT, 80.9% in inpatient, and 74.5% in outpatient programs. By 
primary drug, smoking rates were 85.1% for opiates, 80.9% for alcohol and other drugs, and 
75.2% for alcohol. Regression results are reported in Table 2. The unadjusted ORs in the 
first column show that treatment modality was not associated with differences in smoking 
rates. However, compared to programs treating alcohol, smoking rates were higher in 
programs treating both alcohol and other drug use (OR = 1.75, CI 1.45, 2.11) and in 
programs treating primarily opiate use (OR = 1.84, CI 1.49, 2.28). In Model 1, adjusting for 
year of study, odds of smoking were higher in ORT as compared to outpatient programs (OR 
= 1.42, CI 1.19, 1.68). In Model 2, compared to programs treating alcohol, smoking rates 
were higher in programs treating alcohol and other drug use (OR = 1.83, CI 1.52, 2.21) and 
in programs treating opiate use (OR = 2.52, CI 2.00, 3.17). In Model 3, only persons in 
programs treating alcohol and other drug use showed a higher rate of smoking, as compared 
those in programs treating alcohol use. Neither ORT modality nor opiate as primary drug 
was associated with smoking, and we believe this is because the two variables are 
confounded. In all adjusted models, year of study was inversely associated with smoking 
prevalence, such that the odds of smoking decreased by 6% per year in addiction treatment 
samples (OR = 0.94, CI = 0.93, 0.96). We discount this result because the 51 papers are 
spread across 20 years, and across countries with wide variation in population smoking 
rates. A large study reported in one year can affect the estimate of addiction treatment 
smoking prevalence for that year, influencing an estimate of linear change over time.
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In every study reviewed, smoking prevalence among persons enrolled in addiction treatment 
was 2 to 4 times higher than that in the general population. This is consistent with results 
from the U.S., where NSDUH estimates of smoking among persons receiving addiction 
treatment (1987 – 2009) ranged across years from 66.9% to 75%(43). Considering both the 
prior U.S. review and the current international review, 96 papers reporting from 21 countries 
show that smoking prevalence is higher in addiction treatment as compared to the general 
population. World-wide, smoking among persons in addiction treatment programs 
contributes prominently to the tobacco epidemic, and to associated economic costs and 
morbidity and mortality.
Further, among persons enrolled in addiction treatment programs internationally, the highest 
rates of smoking are associated with opiate use and with participation in ORT programs. 
These findings are also consistent with prior research (16, 43), including findings that 
nicotine appears to potentiate the effect of methadone on opiate withdrawal (49), and that 
peak smoking rates are observed during methadone administration (50).
There are many potential reasons why smoking prevalence is higher in addiction treatment 
populations than in general populations. Like many drugs of abuse, smoking increases 
dopamine levels in reward regions of the brain, and dopamine receptor genes mediate 
smoking as well as other addiction-related behaviors (51). Smokers who also use other drugs 
are more heavily addicted to nicotine than smokers who do not (52, 53); and smokers who 
are more dependent on other drugs, and thus more likely to enter addiction treatment, are 
less successful in quitting smoking (53, 54). Importantly, Prochaska et al. also found that 
receipt of smoking cessation services was associated with improved outcomes for other 
addictions (55).
For patients in addiction treatment, other factors may support continued smoking or interfere 
with efforts to quit. These include elevated smoking prevalence among patients (43) and 
staff (56), and limited access to smoking cessation treatment (57-59). In a meta-analysis of 
smoking cessation trials among persons who received addiction treatment, Prochaska et al. 
found quit rates lower than those achieved in general population samples receiving similar 
treatments (55). Staff attitudes and beliefs about smoking may contribute to lower successful 
quit rates among persons in addiction treatment. Staff who smoke are less likely to address 
smoking with patients (60), and less likely to support smoking cessation in the context of 
addiction treatment (61). Both staff and directors sometimes express attitudes that quitting 
smoking hinders recovery from other addictions, that smoking cessation is a low priority, 
and that patients are not interested in quitting smoking (56). Importantly, many of the same 
attitudinal barriers to addressing smoking in addiction treatment programs are also reported 
in mental health programs (62, 63). Whether difficulty in quitting in addiction treatment 
populations is due to biological factors, features of the addiction treatment culture, or 
provider misconceptions, interventions specially tailored to this population may be needed to 
improve both motivation to quit smoking and successful quit rates.
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Much of this research comes from the U.S. and some findings, particularly concerning the 
culture and beliefs within addiction treatment systems, may not apply internationally. At the 
same time the consistent finding of elevated smoking prevalence in addiction treatment 
internationally suggests that at least some of the contributing factors identified in the U.S. 
literature may apply in addiction treatment systems in other countries.
Limitations of the current study include reliance on English language publications, as this 
excludes an unknown number of reports in other languages which may meet inclusion 
criteria. Search procedures may have missed an unknown number of relevant papers, 
particularly if tobacco was not mentioned in the abstract but smoking prevalence was later 
reported in the paper itself. All smoking prevalence rates were provided in the papers or 
calculated from information provided in the papers. In one instance the prevalence estimate 
included former as well as current smokers (30). In another, smoking prevalence was 
inferred from a tobacco dependence scale (41). When developing national prevalence rates 
for comparison, a simple algorithm determined use of male, female, or combined national 
smoking prevalence. This may result in a national prevalence estimate that is either higher or 
lower than a national prevalence estimate based on the gender proportion in the sample. 
National smoking estimates do not consider differences in socioeconomic status (SES) 
between the general population and addiction treatment samples. If matched to SES of each 
treatment sample by year and by country, national estimates may be higher due to an 
association between lower SES and smoking in most countries (64). In that case, the gap 
between smoking in addiction treatment and smoking in national samples may be smaller. 
Each paper reported on a unique sample and, while we gathered all possible papers, we do 
not assert that any single sample or collection of papers represents smoking prevalence 
among all persons in addiction treatment in a single country.
Findings may inform tobacco control strategies in different countries. Addiction treatment 
programs offer a strategic point for tobacco intervention due to their high smoking 
prevalence and the potential to reach a large number of smokers. To better understand 
smoking prevalence in these populations, the WHO may wish to include a question in the 
GATS similar to that included in the NSDUH, which asks whether the respondent received 
any addiction treatment in the past year (65). When combined with current smoking status, 
this permits estimation of smoking prevalence in addiction treatment populations at the 
national level (43). The WHO, or individual FCTC signatories, may also consider adapting 
the MPOWER strategies, particularly smoke-free environments and cessation programs, for 
use in addiction treatment systems.
Even tobacco control efforts that are effective for the general public may have less success 
when applied to subpopulations such as addiction treatment clients. There is scant 
information, however, about strategies and success rates for addressing smoking in this 
population internationally. This paper is a first step toward encouraging dialogue among 
countries regarding ways to improve the efficacy of tobacco control for addiction treatment 
populations.
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